CLColgate-Palmolive
Colgate-Palmolive Company (together with its subsidiaries, “we,” “us,” “our,” the “Company” or “Colgate-Palmolive”) is a caring, innovative growth company united behind our purpose to reimagine a healthier future for all people, their pets and our planet. 10-K, Item 1
- Employees
- 33,600
- Headquarters
- New York, NY
- CEO
- Noel R. Wallace
- Next results
- around Jan 29, 2027
What CL's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Facts only; most of these sales are routine, such as selling shares from vesting stock awards.
Trading plans adopted or ended
| Insider | What | Date | Shares | Runs to | Reported in |
|---|---|---|---|---|---|
| Jennifer M. Daniels Chief Legal Officer and Secretary |
Adopted 10b5-1 plan | May 1, 2025 | up to 6,000 | Dec 5, 2025 | 10-Q Aug 1, 2025 |
The company's descriptionOn May 1, 2025, Jennifer M. Daniels, the Company’s Chief Legal Officer and Secretary, entered into a pre-arranged trading plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the “10b5-1 Plan”) as part of her long-term asset diversification, tax and financial planning strategy. The 10b5-1 Plan provides for the sale, subject to certain price limits, of up to 6,000 shares of the Company’s common stock in the aggregate and terminates on December 5, 2025, unless terminated sooner in accordance with its terms. The 10b5-1 Plan was entered into during an open insider trading window and no sales will commence under the plan until completion of the required cooling off period under Rule 10b5-1. | |||||
| Noel R. Wallace Chairman, President and Chief Executive |
Adopted 10b5-1 plan | Aug 21, 2024 | up to 100,000 | May 23, 2025 | 10-Q Oct 25, 2024 |
The company's descriptionOn August 21, 2024, Noel R. Wallace, the Company’s Chairman, President and Chief Executive Officer, entered into a pre-arranged trading plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the “10b5-1 Plan”). The 10b5-1 Plan provides for the sale, subject to certain price limits, of up to 100,000 shares of the Company’s common stock in the aggregate and terminates on May 23, 2025, unless terminated sooner in accordance with its terms. The 10b5-1 Plan was entered into during an open insider trading window and no sales will commence under the plan until completion of the required cooling off period under Rule 10b5-1. Mr. Wallace entered into the 10b5-1 Plan as part of his long-term asset diversification, tax and financial planning strategy. Assuming all shares subject to the 10b5-1 Plan are sold, Mr. Wallace will continue to be meaningfully invested in the Company’s stock and will continue to significantly exceed the Company’s rigorous stock ownership guidelines, which require Mr. Wallace to maintain stock ownership of at least eight times his annual base salary. | |||||
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since Apr 28, 2023.
Form 144 notices of planned sales
| Filed | Seller | Shares | Value | Shares came from | 10b5-1 plan | Form 4 sales after |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | NORRINGTON LORRIE M Officer |
4,170 | $414,123 | Exercise of employee stock options | none given | 4,170 shares from Nov 5, 2026 |
| Nov 5, 2026 | Wallace Noel R. Officer |
20,000 | $2,005,163 | Vesting of restricted stock unit awards | none given | 20,000 shares from Nov 5, 2026 |
| Nov 4, 2026 | Tsourapas Panagiotis Officer |
19,938 | $1,968,710 | Exercise of employee stock options | none given | 19,938 shares from Nov 4, 2026 |
| Nov 4, 2026 | Hazlin John Officer |
23,376 | $2,317,683 | Exercise of employee stock options | none given | 23,376 shares from Nov 4, 2026 |
| Aug 24, 2026 | Tsourapas Panagiotis Officer |
10,000 | $920,477 | Vesting of performance share unit awards; Vesting of restricted stock unit awards | none given | 10,000 shares from Aug 24, 2026 |
| Aug 6, 2026 | CAHILL JOHN T Director |
4,170 | $389,358 | Exercise of employee stock options | none given | 4,170 shares from Aug 6, 2026 |
| Aug 5, 2026 | Wallace Noel R. Officer |
161,021 | $14,897,912 | Exercise of employee stock options | none given | 161,021 shares from Aug 5, 2026 |
| Aug 4, 2026 | Wallace Noel R. Officer |
161,021 | $14,800,720 | Exercise of employee stock options | none given | 322,042 shares from Aug 4, 2026 |
| Aug 4, 2026 | CAHILLANE STEVEN A Officer |
1,762 | $159,584 | Exercise of employee stock options | none given | none found |
| Feb 12, 2026 | Tsourapas Panagiotis Officer |
15,000 | $1,467,111 | Exercise of employee stock options | none given | none found |
| Feb 11, 2026 | Tsourapas Panagiotis Officer |
35,000 | $3,311,325 | Exercise of employee stock options | none given | none found |
| Feb 10, 2026 | Hazlin John Officer |
20,989 | $1,978,211 | Exercise of employee stock options | none given | none found |
| Feb 4, 2026 | Daniels Jennifer Officer |
22,000 | $2,075,398 | Exercise of employee stock options | none given | none found |
| Feb 4, 2026 | Wallace Noel R. Officer, Director |
45,568 | $4,279,497 | Vesting of performance share unit award | none given | none found |
| Feb 4, 2026 | SUTULA STANLEY J III Officer |
97,843 | $9,223,284 | Exercise of employee stock options | none given | none found |
From the Form 144 XML filed with the SEC, since Feb 4, 2026. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Work on CL in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/CL/export.csv") into a cell.